Build status - In Progress

A Randomized OPen-label Active controlled Multi-center Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation

A Randomized OPen-label Active controlled Multi-center Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation
Recruiting
1 years - 99 years
All
1 Location

Brief description of study

In order to achieve 200 per-protocol subjects, approximately 250 eligible subjects, age 18 years or older, with a history of paroxysmal or persistent NVAF who are scheduled to undergo an elective catheter ablation procedure will randomize in a 1:1 ratio to receive either rivaroxaban 20 mg orally, once-daily, preferably administered with the evening meal or uninterrupted VKA (adjusted to achieve a recommended INR of 2.0 to 3.0). Subjects not randomized to the rivaroxaban arm of the study will be initiated on, transitioned to (if not already on a VKA) or will continue to receive their usual care regimen of uninterrupted VKA.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Atrial Fibrillation
  • Age: 1 years - 99 years
  • Gender: All
Updated on 04 Aug 2024. Study ID: 817681

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center